Regan J. Lauer - 15 Dec 2023 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Chief Accounting Officer
Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Issuer symbol
IBRX
Transactions as of
15 Dec 2023
Net transactions value
$0
Form type
4
Filing time
19 Dec 2023, 16:41:41 UTC
Previous filing
06 Sep 2023
Next filing
02 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +21,030 +39% $0.000000 74,932 15 Dec 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -21,030 -50% $0.000000 21,031 15 Dec 2023 Common Stock 21,030 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2 Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024.